Biblio
Export 1937 results:
Author Title Type [ Year] Filters: First Letter Of Last Name is B [Clear All Filters]
“Can Diet Supplements of Macular Pigment of Lutein, Zeaxanthin, and Meso-zeaxanthin Affect Cognition?”, J Alzheimers Dis, vol. 87, no. 3, pp. 1079-1087, 2022.
, “Cancer and Vascular Comorbidity Effects on Dementia Risk and Neuropathology in the Oldest-Old.”, J Alzheimers Dis, vol. 90, no. 1, pp. 405-417, 2022.
, “Caregiver Tele-Assistance for Reduction of Emotional Distress During the COVID-19 Pandemic. Psychological Support to Caregivers of People with Dementia: The Italian Experience.”, J Alzheimers Dis, vol. 85, no. 3, pp. 1045-1052, 2022.
, “Cerebrospinal Fluid Sphingomyelins in Alzheimer's Disease, Neurodegeneration, and Neuroinflammation.”, J Alzheimers Dis, vol. 90, no. 2, pp. 667-680, 2022.
, “Cerebrospinal Fluid Sphingomyelins in Alzheimer's Disease, Neurodegeneration, and Neuroinflammation.”, J Alzheimers Dis, vol. 90, no. 2, pp. 667-680, 2022.
, “Cerebrospinal Fluid Sphingomyelins in Alzheimer's Disease, Neurodegeneration, and Neuroinflammation.”, J Alzheimers Dis, vol. 90, no. 2, pp. 667-680, 2022.
, “Characterization of Mild Cognitive Impairment and Dementia among Community-Dwelling Mexican Americans and Non-Hispanic Whites.”, J Alzheimers Dis, vol. 90, no. 2, pp. 905-915, 2022.
, “Characterization of Mild Cognitive Impairment and Dementia among Community-Dwelling Mexican Americans and Non-Hispanic Whites.”, J Alzheimers Dis, vol. 90, no. 2, pp. 905-915, 2022.
, “Circulating Cell-Free Genomic DNA Is Associated with an Increased Risk of Dementia and with Change in Cognitive and Physical Function.”, J Alzheimers Dis, vol. 89, no. 4, pp. 1233-1240, 2022.
, “Clinical and Imaging Determinants of Neurocognitive Disorders in Post-Acute COVID-19 Patients with Cognitive Complaints.”, J Alzheimers Dis, vol. 87, no. 3, pp. 1239-1250, 2022.
, “Clinical Utility of Cerebrospinal Fluid Aβ42 and Tau Measures in Diagnosing Mild Cognitive Impairment in Early Onset Dementia.”, J Alzheimers Dis, vol. 87, no. 2, pp. 771-780, 2022.
, “Combinational Drug Repurposing from Genetic Networks Applied to Alzheimer's Disease.”, J Alzheimers Dis, vol. 88, no. 4, pp. 1585-1603, 2022.
, “Comparative Analysis of Alzheimer's Disease Cerebrospinal Fluid Biomarkers Measurement by Multiplex SOMAscan Platform and Immunoassay-Based Approach.”, J Alzheimers Dis, vol. 89, no. 1, pp. 193-207, 2022.
, “A Comparison of Behavioral and Psychological Symptoms of Dementia (BPSD) and BPSD Sub-Syndromes in Early-Onset and Late-Onset Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 691-699, 2022.
, “A Comparison of Behavioral and Psychological Symptoms of Dementia (BPSD) and BPSD Sub-Syndromes in Early-Onset and Late-Onset Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 691-699, 2022.
, “Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil.”, J Alzheimers Dis, vol. 90, no. 1, pp. 161-172, 2022.
, “A Comparison of Well-Being of Carers of People with Dementia and Their Ability to Manage Before and During the COVID-19 Pandemic: Findings from the IDEAL Study.”, J Alzheimers Dis, vol. 88, no. 2, pp. 679-692, 2022.
, “A Comparison of Well-Being of Carers of People with Dementia and Their Ability to Manage Before and During the COVID-19 Pandemic: Findings from the IDEAL Study.”, J Alzheimers Dis, vol. 88, no. 2, pp. 679-692, 2022.
, “COVID-19 and Neurodegenerative Diseases: Prion-Like Spread and Long-Term Consequences.”, J Alzheimers Dis, vol. 88, no. 2, pp. 399-416, 2022.
, “Demonstration of Clinical Meaningfulness of the Integrated Alzheimer's Disease Rating Scale (iADRS): Association Between Change in iADRS Scores and Patient and Caregiver Health Outcomes.”, J Alzheimers Dis, vol. 88, no. 2, pp. 577-588, 2022.
, “Diabetic Retinopathy Predicts Risk of Alzheimer's Disease: A Danish Registry-Based Nationwide Cohort Study.”, J Alzheimers Dis, vol. 86, no. 1, pp. 451-460, 2022.
, “Does Loss of Integrity of the Cingulum Bundle Link Amyloid-β Accumulation and Neurodegeneration in Alzheimer's Disease?”, J Alzheimers Dis, vol. 89, no. 1, pp. 39-49, 2022.
, “Effect of Probiotic Bifidobacterium breve in Improving Cognitive Function and Preventing Brain Atrophy in Older Patients with Suspected Mild Cognitive Impairment: Results of a 24-Week Randomized, Double-Blind, Placebo-Controlled Trial.”, J Alzheimers Dis, vol. 88, no. 1, pp. 75-95, 2022.
, “The Effectiveness of GRADIOR: A Neuropsychological Rehabilitation Program for People with Mild Cognitive Impairment and Mild Dementia. Results of a Randomized Controlled Trial After 4 and 12 Months of Treatment.”, J Alzheimers Dis, vol. 86, no. 2, pp. 711-727, 2022.
, “The Effectiveness of GRADIOR: A Neuropsychological Rehabilitation Program for People with Mild Cognitive Impairment and Mild Dementia. Results of a Randomized Controlled Trial After 4 and 12 Months of Treatment.”, J Alzheimers Dis, vol. 86, no. 2, pp. 711-727, 2022.
,